Co-Authors
This is a "connection" page, showing publications co-authored by CLAUDIO ESTEVES TATSUI and TINA MARIE BRIERE.
Connection Strength
0.516
-
Validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic body radiation. Radiother Oncol. 2024 Oct 02; 201:110570.
Score: 0.062
-
Definitive single fraction spine stereotactic radiosurgery for metastatic sarcoma: Simultaneous integrated boost is associated with high tumor control and low vertebral fracture risk. Radiother Oncol. 2024 04; 193:110119.
Score: 0.059
-
Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery. J Neurooncol. 2023 Sep; 164(2):377-386.
Score: 0.057
-
Safety and efficacy of salvage conventional re-irradiation following stereotactic radiosurgery for spine metastases. Radiat Oncol J. 2023 Mar; 41(1):12-22.
Score: 0.056
-
Safety and Efficacy of Dose-Escalated Radiation Therapy With a Simultaneous Integrated Boost for the Treatment of Spinal Metastases. Pract Radiat Oncol. 2023 Jan-Feb; 13(1):e7-e13.
Score: 0.054
-
Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously irradiated metastatic epidural spinal cord compression. N Am Spine Soc J. 2021 Jun; 6:100066.
Score: 0.049
-
Low risk of radiation myelopathy with relaxed spinal cord dose constraints in de novo, single fraction spine stereotactic radiosurgery. Radiother Oncol. 2020 11; 152:49-55.
Score: 0.046
-
Spine stereotactic radiosurgery for metastases from hepatobiliary malignancies: patient selection using PRISM scoring. J Neurooncol. 2020 Jun; 148(2):327-334.
Score: 0.046
-
Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience. J Neurosurg Spine. 2020 06 01; 32(6):941-949.
Score: 0.045
-
Low incidence of late failure and toxicity after spine stereotactic radiosurgery: Secondary analysis of phase I/II trials with long-term follow-up. Radiother Oncol. 2019 09; 138:80-85.
Score: 0.043